美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物科技指数ETF-iShares Nasdaq

200.85

-3.4100-1.67%

成交量：55.28万

成交额：1.11亿

市值：105.35亿

市盈率：31.82

高：203.91

开：203.76

低：200.11

收：204.26

52周最高：217.12

52周最低：149.09

股本：5,245.00万

流通股本：5,245.00万

量比：0.32

换手率：1.05%

股息：0.35

股息率：0.17%

每股收益(TTM):6.31

每股收益(LYR):35.34

净资产收益率：24.54%

总资产收益率：0.10%

市净率：1.29

市盈率(LYR):5.68

数据加载中...

总览公司新闻资讯公告

复星医药子公司携生物类似药出海牵手全球仿制药龙头，锁定四成销售分成

每日经济新闻

复宏汉霖与山德士达成战略合作

argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果

巴克莱上调安进目标价至380美元

复宏汉霖拟向山德士授权至多10款生物类似药，国产生物药国际化再进一步｜医药早参

每日经济新闻

复宏汉霖携手Sandoz布局生物类似药首批3款产品落地

复星医药：控股子公司与Sandoz AG达成至多10款生物类似药许可合作，首批3款产品首付款及里程碑款至多2.37亿美元

Assembly股价上涨，因季度营收超出预期

中国银河证券：实验动物为创新药研发刚需小鼠+猴双主线高景气

百花医药股价严重异常波动：主营小分子化学仿制药CRO业务不涉及创新药研发

MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项

数据简报-全球制药企业斥资数十亿以扩大在美业务

Tango因季度亏损额超出预期而股价下跌

百花医药(600721.SH)：不涉及创新药研发

百花医药(600721.SH)：不涉及创新药研发

东方证券：AI重构创新药研发底座国内相关产业链公司亦有望受益

百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用

美股异动 | 因竞争对手的药物研发未达目标福泰制药(VRTX.US)涨近7%

美股异动 | 因竞争对手的药物研发未达目标福泰制药(VRTX.US)涨近7%

福泰制药(VRTX)股票8月10日开盘上涨9.76%：投资者必看的核心信息

TradingKey中文

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IBB/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":200.85,"timestamp":1791916411029,"preClose":204.26,"halted":0,"volume":552845,"delay":0,"changeRate":-0.01669440908645842,"floatShares":52450000,"shares":52450000,"eps":6.311863,"marketStatus":"交易中","change":-3.41,"latestTime":"10-13 14:33:31 EDT","open":203.755,"high":203.91,"low":200.11,"amount":111346946.89865,"amplitude":0.018604,"askPrice":200.93,"askSize":160,"bidPrice":200.88,"bidSize":100,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":204.26,"sharesOutstanding":49450000,"nav":206.296467,"aum":10840879340.85,"dividendRate":0.001729,"bidAskSpread":0.000349,"preHourTrading":{"tag":"盘前","latestPrice":203.8,"preClose":204.26,"latestTime":"09:29 EDT","volume":282,"amount":57569.273519999995,"timestamp":1791898199999,"change":-0.46,"changeRate":-0.002252,"amplitude":0.009889},"postHourTrading":{"tag":"盘后","latestPrice":204.26,"preClose":204.26,"latestTime":"19:47 EDT","volume":10034,"amount":2049515.9148,"timestamp":1791848828793,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.318088,"impliedVol":0.2359,"impliedVolPercentile":0.4661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":52450000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":0.318088,"shares":52450000,"dividePrice":0.3472,"high":203.91,"amplitude":0.018604,"preClose":204.26,"low":200.11,"week52Low":149.0909,"pbRate":"1.29","psRate":"253.45","week52High":217.12,"institutionHeld":0,"latestPrice":200.85,"committee":-0.230769,"eps":6.311863,"divideRate":0.001729,"volume":552845,"delay":0,"ttmEps":6.311863,"open":203.755,"prevYearClose":168.77,"prevWeekClose":206.49,"prevMonthClose":210.53,"prevQuarterClose":210.53,"fiveDayClose":203.1,"twentyDayClose":202,"sixtyDayClose":186.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-07-02","value":0.15606,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660866704","title":"复星医药子公司携生物类似药出海 牵手全球仿制药龙头，锁定四成销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2660866704","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660866704?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 17:26","pubTimestamp":1786958770,"startTime":"0","endTime":"0","summary":"8月17日，复星医药（SH600196，股价24.01元，市值588.9亿元）公告披露，其控股子公司复宏汉霖与全球生物类似药龙头SandozAG于8月16日签订《合作框架协议》。双方约定，可就复宏汉霖至多10款单克隆抗体（mAb）和/或抗体偶联药物（ADC）生物类似药，开展海外区域的注册、商业化、开发、生产等许可合作，并已就首批3款产品达成具体商业条款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843260444.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843260444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731600.USD","LU2322448791.USD","600196","BK0196","LU2473716301.USD","LU2272731782.SGD","BK4585","02196","LU2272731865.HKD","XPH","BK1515","BK1593","BK0188","BK0187","BK0175","BK1191","LU1992135399.USD","BK4588","BK0183","BK0012","BK0028","BK0239","LU2322448957.HKD","PPH","LU1992135472.HKD","BK0060","IE00B5TLWC47.USD","BK0096","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660857514","title":"复宏汉霖与山德士达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660857514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660857514?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 17:05","pubTimestamp":1786957508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5TLWC47.USD","IBB","LU2272731782.SGD","BK4585","XPH","LU2272731600.USD","LU2322448791.USD","PPH","LU2322448957.HKD","BK4588","LU2473716301.USD","LU1992135472.HKD","LU2272731865.HKD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660853994?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","FMED","BK4585","LU0109394709.USD","LU2324357040.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","BK4505","IE0034235188.USD","BK4588","IE0009355771.USD","LU1983260115.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU0823416689.USD","IBB","LU0320765992.SGD","ARGX","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101358","title":"巴克莱上调安进目标价至380美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101358","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101358?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 11:05","pubTimestamp":1786935953,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4139","AMGN","IE00BFTCPJ56.SGD","PBE","SG9999001440.SGD","BK4585","BIB","LU0320765992.SGD","LU2112291526.USD","BK4534","BK4566","IE0002141913.USD","IBBQ","LU2089984988.USD","UUP","IBB","TBXU","BK4599","BK4533","LU0868494617.USD","LU1571399168.USD","BBH","UDN","LU1023059063.AUD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","PJP","BK4581","IE00BJJMRZ35.SGD","LU1057294990.SGD","BK4588","LU0289739699.SGD","LU2468319806.SGD","LU1061106388.HKD","LU0122379950.USD","LU0058720904.USD","LU1983299246.USD","LU2242652126.USD","LU0889565916.HKD","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660106203","title":"复宏汉霖拟向山德士授权至多10款生物类似药，国产生物药国际化再进一步｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2660106203","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660106203?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 09:33","pubTimestamp":1786930438,"startTime":"0","endTime":"0","summary":"过去一周（截至8月14日收盘），创新药板块震荡上行。打包医药全产业链的医药ETF（512120）上涨0.2%，聚焦A股创新药的生物医药ETF（159508）上涨1.77%，聚焦港股创新药的港股通生物科技ETF（159102）上涨0.12%。相关个股中，康龙化成上涨8.48%、药明康德上涨2.85%、恒瑞医药下跌3.66%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842706171.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842706171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731600.USD","LU2322448791.USD","LU2473716301.USD","HK0000320264.USD","LU2272731782.SGD","BK4585","BK1574","LU2272731865.HKD","XPH","159839","BK1515","BK1161","HK0000306701.USD","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD","02696","LU1992135399.USD","BK4588","LU2322448957.HKD","PPH","159938","09939","LU1992135472.HKD","IE00B5TLWC47.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110620","title":"复宏汉霖携手Sandoz布局生物类似药 首批3款产品落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110620","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110620?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 09:22","pubTimestamp":1786929720,"startTime":"0","endTime":"0","summary":"8月17日，复宏汉霖（02696）发布公告，公司于2026年8月16日与SandozAG达成战略合作框架协议，预计2026年可实现的开票金额总计不超过1.01亿元美元。此次合作开发最多10款单抗和/或ADC生物类似药相关产品，后续针对各个产品另行签订附属协议确定具体合作条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842662937.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842662937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000320264.USD","HK0000320223.HKD","LU1992135472.HKD","LU2473716301.USD","02696","BK4585","HK0000165453.HKD","LU2322448957.HKD","LU1992135399.USD","LU2322448791.USD","LU2272731865.HKD","XPH","BK1161","BK4588","HK0000306701.USD","IBB","LU2272731600.USD","HK0000306685.HKD","IE00B5TLWC47.USD","LU2272731782.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660219103","title":"复星医药：控股子公司与Sandoz AG达成至多10款生物类似药许可合作，首批3款产品首付款及里程碑款至多2.37亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660219103","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660219103?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 07:48","pubTimestamp":1786924110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SLVR","LU1992135472.HKD","SLJY","LU2473716301.USD","BK4585","LU2322448957.HKD","LU1992135399.USD","LU2322448791.USD","AG","LU2272731865.HKD","XPH","BK4210","BK4588","IBB","LU2272731600.USD","IE00B5TLWC47.USD","LU2272731782.SGD","SLVX","PPH","SILJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659400001","title":"Assembly股价上涨，因季度营收超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2659400001","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659400001?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 23:25","pubTimestamp":1786721141,"startTime":"0","endTime":"0","summary":"BUZZ-Assembly股价上涨，因季度营收超出预期8月14日-** 药物研发公司Assembly Biosciences（ASMB.O）股价上涨4.6%，报31.32美元** ASMB第二季度与吉利德（GILD.O）合作研究的收入为1340万美元，高于去年同期的960万美元** 据LSEG数据显示，分析师此前平均预期营收为860万美元** 公司表示，营收增长包括针对吉利德合作项目下未来活动最新预估所作的510万美元补足调整** 报告显示第二季度每股亏损20美分，而市场预期为每股亏损65美分** 计入当日涨幅后，该股年初至今累计上涨11.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL4S44B103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0114720955.EUR","IBBQ","LU0109394709.USD","IE00B3T34201.USD","TMED","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU1585245621.USD","BIB","LU0234570918.USD","BBH","LU0965509283.SGD","LU0965509101.SGD","IBB","LU1061106388.HKD","SG9999015952.SGD","BK4550","LU0058720904.USD","LU2087621335.USD","LU0861579265.USD","LU1934455277.USD","SG9999015986.USD","LU0965508806.USD","BK4588","LU1839511570.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1037948541.HKD","MEDI","LU0122379950.USD","BK4583","ASMB","LU1066053197.SGD","LU1037948897.HKD","LU2324357040.USD","LU0289739699.SGD","LU1066051498.USD","IE00BSNM7G36.USD","BK4568","BK4532","BMED","BK4585","BK4578","LU2112291526.USD","SG9999015945.SGD","TBXU","LU0889565916.HKD","BK4139","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659504119?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PBE","SBIO","BBP","BK0188","GDOC","XLVI","APXH","BK1564","WRND","BK0276","161027","IBB","BK4585","LFSC","601881","BK4588","06881","BIOY","BK1147","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动：主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903675?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PBE","600721","APXH","BK0216","BK4585","LFSC","XLVI","GSKH","BK4588","GDOC","BIOY","WRND","BK0102","IBB","SBIO","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658465479","title":"MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2658465479","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658465479?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 05:18","pubTimestamp":1786483082,"startTime":"0","endTime":"0","summary":"BUZZ-MacroGenics股价上涨，因吉利德支付了1000万美元的里程碑款项8月11日-** 药物开发商MacroGenics（MGNX.O）的股价在盘后交易中上涨3.8%，至4.07美元** 该公司表示，根据其与吉利德（GILD.O）就一项临床前双特异性项目（一种癌症疗法）达成的许可协议，已收到1000万美元的里程碑付款** 根据2022年签署的合作协议，MacroGenics与吉利德正在推进三个项目：处于临床阶段的抗癌疗法MGD024，以及两个处于临床前阶段的双特异性项目** MGNX仍有资格获得最高约16亿美元的额外开发、监管及商业里程碑付款** 今年以来，该公司股价已翻了一番多","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481IH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1023059063.AUD","SG9999015986.USD","TMED","MGNX","LU1571399168.USD","LU0234570918.USD","BK4532","LU2087621335.USD","LU2468319806.SGD","BK4139","LU0058720904.USD","BK4550","LU1066051498.USD","MEDI","IE0002270589.USD","LU0882574055.USD","BBH","LU0289739699.SGD","LU1585245621.USD","IE00B7SZLL34.SGD","LU1674673691.USD","LU2324357040.USD","LU0965508806.USD","LU1778281490.HKD","IE00BKVL7J92.USD","IE00B19Z3581.USD","TBXU","BK4566","GILD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU1839511570.USD","BK4578","LU0965509101.SGD","BK4588","SG9999015952.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","SG9999015945.SGD","BK4585","LU1934455863.HKD","LU1674673428.USD","BMED","LU0114720955.EUR","LU2089984988.USD","SG9999015978.USD","BIB","IBBQ","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658591102","title":"数据简报-全球制药企业斥资数十亿以扩大在美业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2658591102","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658591102?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 23:59","pubTimestamp":1786463961,"startTime":"0","endTime":"0","summary":"数据简报-全球制药企业斥资数十亿以扩大在美业务更新了第18段中关于百健生产工厂的数据路透8月11日-全球制药企业正扩大在美国的业务布局，承诺投入数十亿美元以提升该国的生产能力和研发实力。该公司于6月表示，已在佛罗里达州杰克逊维尔投资约10亿美元，以加强其眼科护理业务在美国的制造能力。这家制药公司宣布将投资 6.5 亿美元 ，以扩大其位于波多黎各洪科斯工厂的药品生产规模，此举预计将创造近 750 个就业岗位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S448167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1057294990.SGD","LU0345770993.USD","SG9999011175.SGD","PBE","LU0234572021.USD","LU0859254822.USD","SG9999018865.SGD","LU0114720955.EUR","LU0964807845.USD","LU2236285917.USD","LU0912757837.SGD","LU2361045086.USD","SG9999015358.SGD","LU2023250843.SGD","IE0034235303.USD","BK4007","LU0738911758.USD","LU1868837300.USD","LU0672654240.SGD","LLYZ","LU1496350502.SGD","LU2746668461.USD","BK4581","LU2125154778.USD","LU0211328371.USD","LU1061106388.HKD","LU1839511570.USD","OZEM","LU1974910355.USD","BK4533","LU0882574055.USD","SG9999014880.SGD","LU1196500208.SGD","LU1548497426.USD","LU0198837287.USD","IE00BKPKM429.USD","BK4532","LU2089284900.SGD","IE00BN29S564.USD","XLV","LU0265550359.USD","SG9999001176.SGD","IE0004445239.USD","LU0058720904.USD","LU0353189680.USD","LU2271345857.HKD","SG9999017495.SGD","LU2596442595.SGD","LU2461242641.AUD","BK4599","LU1280957306.USD","LU2505996681.GBP","LU0170899867.USD","LU0106261372.USD","LU0353189763.USD","IE00BWXC8680.SGD","LU0323591593.USD","BK4139","IE00B19Z3581.USD","LU1712237335.SGD","LU0210528500.USD","IE00BKVL7J92.USD","LU1670710661.SGD","SG9999003800.SGD","LU0130517989.USD","JNJ","LU0069063385.USD","RXL","LU0316494557.USD","BK4559","LU2264538146.SGD","LU0354030511.USD","LU1979441026.SGD","LU1430594728.SGD","LU2211815571.USD","IE0004445015.USD","LLYX","LU0861579265.USD","IE0002270589.USD","LU1023059063.AUD","LU0174119429.USD","FTXH","LU2112291526.USD","LU0128525929.USD","LU0949170772.SGD","LU2756315664.SGD","SG9999013999.USD","LU0203201768.USD","LU0256863811.USD","PPH","LU1228905540.USD","IE00B3PB1722.GBP","IE000BZT7R73.USD","LU1670711040.USD","LU2237443978.SGD","LU1221951046.USD","LU0823416689.USD","IHE","LU1732800096.USD","MEDX","LU1699723380.USD","BK4578","LU2602419157.SGD","LU1121112475.USD","IE0000B7K699.USD","IE00BFXG1179.USD","LU1267930730.SGD","LU0289961442.SGD","LU0057025933.USD","LU2168564149.EUR","LU2433249047.HKD","LU1221951129.SGD","TBXU","PJP","LU1506573853.SGD","LU0994945656.USD","LU0545562505.USD","LU0289739699.SGD","SG9999015945.SGD","LU1718418525.SGD","IE0009355771.USD","LU2023250504.SGD","LU1037948897.HKD","FHLC","LU0079474960.USD","LU1804176565.USD","LU0792757196.USD","LU1228905037.USD","SGXZ80539844.SGD","BK4516","LU1914381329.SGD","LU0786609619.USD","IE00BK4W5M84.HKD","LU0267386448.USD","LU0070302665.USD","LU1571399168.USD","LU2456880835.USD","LU0820561909.HKD","LU2125909247.SGD","LU2023250330.USD","LU2746668974.SGD","BK4592","LU1162221912.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU0094547139.USD","LU0456855351.SGD","LU0395794307.EUR","LU0466842654.USD","GB00BDT5M118.USD","SG9999018857.SGD","LLY","LU0795875086.SGD","SG9999014914.USD","LU0708995401.HKD","IE0005OL40V9.USD","LU0266013472.USD","LU2168564065.EUR","LU1829250122.USD","IE00BFSS8Q28.SGD","LU0096364046.USD","LU1066051225.USD","LU0345769128.USD","IE00BFSS7M15.SGD","LU1267930813.SGD","LU1929549753.HKD","LU2756315318.SGD","LU1267930573.SGD","ELIS","LU0965509283.SGD","LU0061475181.USD","LU1868836757.USD","LU2023251221.USD","TMED","LU0980610538.SGD","IE00B19Z3B42.SGD","LU1670627923.USD","IBBQ","LU1069347547.HKD","LU0787776722.HKD","LU1035773651.USD","LU1814569148.SGD","SG9999014906.USD","LU0225284248.USD","LU2347655073.USD","IYH","LU2133065610.SGD","BBH","BK7067","LU1674673691.USD","LU2360032135.SGD","LU2089283258.USD","IE00BSNM7G36.USD","SGXZ31699556.SGD","LU1261432733.SGD","AZN","LU0210536198.USD","IE00B7SZLL34.SGD","LU0553294199.USD","LU0726765562.USD","IE000WAW04H5.SGD","BK4566","IE00B4JS1V06.HKD","LU0985320562.USD","LU1074936037.SGD","LU1093756325.SGD","SGXZ99366536.SGD","ELIL","LU0306806265.USD","LU2430703251.USD","LU1623119135.USD","SG9999001176.USD","IE00BGHQF631.EUR","LU0320765646.SGD","LU1066051811.HKD","MEDI","LU2111349929.HKD","IE00BZ1G4Q59.USD","LU0545039389.USD","LU2491049909.HKD","LU0097036916.USD","IE000M9KFDE8.USD","LU0823434583.USD","LU2237443465.HKD","LU0345770308.USD","LU0820561818.USD","IE0002141913.USD","IE00BVYPNV92.GBP","LU1894683348.USD","IE00BJJMRZ35.SGD","LU0289739343.SGD","BK7508","LU0225771236.USD","LU2028103732.USD","SG9999014542.SGD","LU0158827948.USD","IE00BVYPNW00.USD","LU1585245621.USD","LU1720051017.SGD","LU0820562030.AUD","LU1934455277.USD","JDOC","IE00BJT1NW94.SGD","LU2237443382.USD","SG9999014567.USD","LU1043141123.HKD","LU1032955483.USD","IE00B42XCP33.USD","LU2552382058.USD","LU0889566641.SGD","LU0070217475.USD","LU0238689110.USD","LU0072461881.USD","LU0965509010.AUD","LU2430703178.SGD","BK4583","LU0098860793.USD","LU2129689605.HKD","LU2324357040.USD","LU1868837136.USD","LU0426417589.USD","LU1989772923.USD","LU2360106947.USD","LU0965508806.USD","LU0943347566.SGD","LU1670710588.SGD","LU2125909593.SGD","LU2125154935.USD","GDOC","LU1670711123.USD","LU1732799900.SGD","LU1894683264.USD","ILDR","IE00BN8TJ469.HKD","LU1934455863.HKD","CSL.AU","LU0203345920.USD","LU2361044949.HKD","LU0320765992.SGD","SG9999015952.SGD","LU0130102774.USD","LU1093756168.USD","LU2471134523.USD","LU2552382132.HKD","LU1035775433.USD","LU1116320737.USD","LU1244550221.USD","BK4534","LU1116320901.HKD","LU2357627491.SGD","LU1989771016.USD","AMGN","LU1291159041.SGD","LU1059921491.USD","BMY","LU0256863902.USD","LU0321505868.SGD","AGNG","IE0001KFT4U8.USD","LU2168563687.JPY","IE00B1XK9C88.USD","LU0965509101.SGD","LU0203347892.USD","BK4588","IE000SO60NU8.SGD","LU0868494617.USD","LU0225283273.USD","LU0320765059.SGD","IE00B19Z9Z06.USD","LU2896262040.SGD","GLAM","LU1629891620.HKD","IE00B7KXQ091.USD","LU2403377893.USD","BIB","LU0471298694.HKD","LU2750360997.AUD","LU1043141396.HKD","SGXZ57979304.SGD","SG9999002224.SGD","LU2168564222.USD","TRUH","LU0124676726.USD","LU0689626769.HKD","LU2089984988.USD","LU0882574139.USD","SG9999001440.SGD","LU2242652126.USD","LU0661504455.SGD","LU0345769631.USD","LU1983299246.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0158827781.USD","LU1883839398.USD","LU1069344957.HKD","LU0211327993.USD","BK4585","04332","LU1232071149.USD","LU0109391861.USD","IE00BJLML261.HKD","LU2129689431.USD","LU2087625088.SGD","LU2168564495.EUR","LU0203202063.USD","LU2487616109.SGD","LU2491050154.USD","LU2592432038.USD","LU1917777945.USD","LU0708994859.HKD","BMED","THNR","LU1923622614.USD","GILD","LU0122379950.USD","LU1145028129.USD","VHT","LU0237698245.USD","IE00BJJMRX11.SGD","PAWZ","LU1988902786.USD","LU0234570918.USD","LU2108987350.USD","IE00B1BXHZ80.USD","LU1674673428.USD","LU0006306889.USD","LU1244550494.USD","MHIP","SG9999014559.SGD","IE00BFTCPJ56.SGD","LU0265550946.USD","LU1064131342.USD","LU0354030438.USD","LU2347655156.SGD","LU1003077747.HKD","LU1496350171.SGD","LU2430703095.HKD","IE00BLSP4452.SGD","SGXZ51526630.SGD","LU0310800379.SGD","AZNH","LU0868494708.USD","LU2213496289.HKD","IE00BBT3K403.USD","WDNA","PFE","IXJ","LU2361044865.SGD","LU2552382215.SGD","SG9999002232.USD","LU2750360641.GBP","SG9999015341.SGD","BK4504","HRTS","LU1670628061.USD","CURE","LU1868836591.USD","IE00BDGV0183.EUR","LU0385154629.USD","LU2063271972.USD","LU0689472784.USD","LU1941712348.USD","IE00B894F039.SGD","LU0472753341.HKD","LU1066051498.USD","IE00BK4W5L77.USD","LU0985481810.HKD","LU1066053197.SGD","BIIB","BK7501","SGXZ81514606.USD","LU1201861249.SGD","LU2242646821.SGD","LU1935042991.SGD","LU0432979614.USD","IE00B19Z9P08.USD","LU2087621335.USD","LU1551013342.USD","LU1037948541.HKD","LU1934455194.USD","LU1244550577.SGD","LU0208291251.USD","LU0310799852.SGD","BK4568","LU2237438978.USD","LU1989772840.SGD","SG9999014575.USD","LU2129689514.USD","IE00BJJMRY28.SGD","LU1778281490.HKD","IE000MB6IJN5.SGD","LU0823434740.USD","LU0640476718.USD","LU1127390331.HKD","BK7511","LU2237443622.USD","LU0306807586.USD","LU1267930490.SGD","LU2491050071.SGD","LU0109394709.USD","LU1868836914.USD","LU2462157665.USD","LU0795875169.SGD","LU2357305700.SGD","CANC","IE00BLSP4239.USD","LU0511384066.AUD","LU1941712264.USD","MRK","IE00B775H168.HKD","IE00BKDWB100.SGD","SG9999014898.SGD","LU1366192091.USD","LU0942090050.USD","LU0320765489.SGD","IE000F7OJYX1.SGD","LU2471134796.USD","LU2237443895.HKD","SG9999015978.USD","LU1323610961.USD","LU0211331839.USD","LU2106854487.HKD","LU0426412945.USD","LU0471298777.SGD","LU0683600562.USD","LLII","LU0162691827.USD","LU2417539215.USD","LU2265009873.SGD","LU0053666078.USD","LU1032466523.USD","LU2237443549.SGD","LU0133085943.USD","LU0417517546.SGD","LU0321505439.SGD","LU1551013425.SGD","LU2471134879.HKD","LU0648001328.SGD","BK4550","IE00B4R5TH58.HKD","LU0029864427.USD","LU0477156953.USD","LU2462591350.SGD","ABBV","SG9999015986.USD","LU1720051108.HKD","LU2471134952.CNY","LU2505996509.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658391156","title":"Tango因季度亏损额超出预期而股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658391156","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658391156?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 23:19","pubTimestamp":1786461555,"startTime":"0","endTime":"0","summary":"BUZZ-Tango因季度亏损额超出预期而股价下跌8月11日-** 药物研发公司Tango TherapeuticsTNGX.O股价下跌3.3%，报26.75美元** 据LSEG数据显示，该公司报告第二季度每股亏损37美分，而分析师平均预期为每股亏损31美分** TNGX报告称，截至2026年6月30日的三个月内未产生合作收入，原因是与吉利德GILD.O的合作关系及研发活动已终止** 该公司202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4T44814U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU2087621335.USD","LU2089984988.USD","LU1674673691.USD","IE00BJJMRZ35.SGD","MEDI","GILD","LU0965508806.USD","BK4588","BBH","BK4583","CANC","LU0861579265.USD","IE0009355771.USD","TBXU","LU1066051498.USD","BIB","LU0109394709.USD","LU2324357040.USD","TNGX","IE00B2B36J28.USD","BK4585","IE0002270589.USD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2468319806.SGD","BK4139","PTH","IBB","LU1934455863.HKD","TMED","LU0889565916.HKD","LU1934455277.USD","LU1066053197.SGD","IE00B19Z3581.USD","SG9999015952.SGD","BMED","LU0965509010.AUD","BK4532","IBBQ","LU0289739699.SGD","LU0234570918.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","LU1037948897.HKD","LU0114720955.EUR","RVMD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","IBB","BK4588","BIOY","GSKH","SBIO","PBE","BBP","GDOC","LFSC","WRND","XLVI","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658667990?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BIOY","BK4585","BBP","GDOC","SBIO","WRND","GSKH","BK0102","APXH","BK4588","PBE","600721","XLVI","IBB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658962968","title":"东方证券：AI重构创新药研发底座 国内相关产业链公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658962968","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658962968?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 14:06","pubTimestamp":1786428403,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：技术颠覆成本，AI重构制药“快与省”是中国创新药崛起的底层逻辑，根基是人才红利和成本优势。专家与AI协同，将真正提升新药研发的成功率并缩短周期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","GDOC","BIOY","BK4585","03958","BK1564","LFSC","GSKH","WRND","BK1147","ARTY","BK0188","SBIO","BK0276","XLVI","BK4588","BK0183","BK0012","AIPO","PBE","BBP","BK0028","600958","AGIX","IBB","VTHR","QTOC","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658196566?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B2B36J28.USD","LU0588546209.SGD","LU1571399168.USD","BK4526","LU0109394709.USD","LU2468319806.SGD","LU2242646821.SGD","LU0307460666.USD","06160","688235","IE00BJT1NW94.SGD","LU1061106388.HKD","BK1500","BK1588","LU2112291526.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","IBB","BBH","BK4599","IE0002141913.USD","LU2089984988.USD","LU1983299246.USD","PBE","BK1583","BK4534","LU0828237510.HKD","TBXU","AMGN","LU0289739699.SGD","ONC","BK4533","LU1057294990.SGD","IBBQ","BK4566","LU0122379950.USD","LU0228659784.USD","LU1770034418.SGD","PJP","KURE","BK1161","LU1023059063.AUD","BIB","BK4139","LU1969619763.USD","BK4585","LU2242652126.USD","LU0058720904.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930620?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z9Z06.USD","BIB","SG9999001176.SGD","BBH","LU0417517546.SGD","LU0889565916.HKD","LU1035775433.USD","BK4585","BK4139","IDNA","LU1674673691.USD","LU2324357040.USD","SG9999013999.USD","SGXZ57979304.SGD","TBXU","IE0002270589.USD","LU0320765992.SGD","LU1585245621.USD","LU1430594728.SGD","LU1069344957.HKD","LU2089984988.USD","IE00B19Z3581.USD","LU0234570918.USD","LU1093756168.USD","VRTX","IBBJ","BK4567","BK4588","IBB","LU0256863811.USD","LU1778281490.HKD","LU0058720904.USD","IBBQ","LU1674673428.USD","LU2462157665.USD","PBE","IE00B19Z9P08.USD","IE0009355771.USD","IE0002141913.USD","IE00BZ9MQY76.HKD","SG9999001176.USD","IE00BJT1NW94.SGD","LU2456880835.USD","LU0289739699.SGD","LU2236285917.USD","LU2417539215.USD","IE00BFTCPJ56.SGD","LU2362541513.USD","LU2362540622.SGD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658793062?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，$福泰制药(VRTX)$(VRTX.US)早盘涨近7%，创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%，创记录新低。消息面上，SION表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁，但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病，会导致肺部进行性损伤。","market":"sh","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2417539215.USD","LU0256863811.USD","LU1778281490.HKD","SG9999013999.USD","LU2456880835.USD","SG9999001176.SGD","BK4567","LU0234570918.USD","LU2468319806.SGD","LU0109394709.USD","LU0320765992.SGD","IE0002141913.USD","IBBQ","PBE","TBXU","LU1430594728.SGD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2462157665.USD","LU0058720904.USD","LU1674673691.USD","LU1093756168.USD","VRTX","BIB","LU2362541513.USD","LU2236285917.USD","LU1585245621.USD","GNMX","LU1674673428.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU2362541273.HKD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","BBH","IE00BZ9MQY76.HKD","BK4532","IBBJ","BK4139","IBB","LU0079474960.USD","IE00B19Z9P08.USD","SG9999001176.USD","IDNA","IE00BFTCPJ56.SGD","IE00B894F039.SGD","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658934147","title":"福泰制药(VRTX)股票8月10日开盘上涨9.76%：投资者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2658934147","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658934147?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 21:48","pubTimestamp":1786369694,"startTime":"0","endTime":"0","summary":"• 福泰制药（Vertex）公布了其非阿片类疼痛治疗候选药物的积极III期临床数据。\n• 在产品于国际市场成功上市后，该公司上调了全年营收指引。\n• 分析师维持“买入”评级，平均目标价为557.64美元。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262092811-market-movers-vrtx-20260810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999013999.USD","IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","LU2324357040.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","LU0234570918.USD","LU0256863811.USD","IE0002270589.USD","SG9999001176.SGD","LU1035775433.USD","IE00B4R5TH58.HKD","LU2236285917.USD","LU2237438978.USD","IBB","BBH","IE0002141913.USD","GNMX","IDNA","LU0823416689.USD","LU2089984988.USD","LU2362541273.HKD","PBE","LU0320765992.SGD","BK4532","IE00B19Z3581.USD","LU2362541513.USD","LU2462157665.USD","TBXU","LU1093756325.SGD","BK4533","LU1585245621.USD","IBBQ","SG9999001176.USD","LU2456880835.USD","LU0889565916.HKD","LU0061475181.USD","LU1093756168.USD","VRTX","LU1778281490.HKD","IE00BJJMRZ35.SGD","BK4567","BIB","BK4139","LU0432979614.USD","BK4585","LU1430594728.SGD","LU0058720904.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}